Ocular Therapeutix, Inc.
HealthcareNASDAQ:OCUL · NASDAQ Global Market
+$0.24 today
Vol 2.69M · Avg 3.04M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$52.0M of revenue converted into -$290.5M of net income for the selected period. Gross margin is 87.3% and net margin is -572.7%, showing how much revenue survives after costs and taxes. EPS is $-1.46, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.8M -18.7% | $63.7M +9.0% | $58.4M +13.5% | $51.5M +18.3% | $43.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $6.6M +16.9% | $5.6M +6.5% | $5.3M +16.3% | $4.5M +3.0% | $4.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $45.2M -22.1% | $58.1M +9.3% | $53.2M +13.2% | $47.0M +20.0% | $39.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 87.3% -3.9pp | 91.2% +0.2pp | 91.0% -0.2pp | 91.2% +1.3pp | 89.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $197.1M +54.4% | $127.6M +109.0% | $61.1M +14.2% | $53.5M +6.7% | $50.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $118.3M +15.7% | $102.2M +37.3% | $74.5M +3.2% | $72.1M +7.6% | $67.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $315.4M +37.2% | $229.9M +69.6% | $135.5M +7.9% | $125.6M +7.2% | $117.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $4.3M +14.2% | $3.8M +26.9% | $3.0M +41.4% | $2.1M -12.9% | $2.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$249.8M -41.8% | -$176.1M -165.2% | -$66.4M -7.3% | -$61.9M -2538.2% | $2.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -482.0% -205.6pp | -276.4% -162.8pp | -113.6% +6.6pp | -120.2% -126.1pp | 5.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$270.0M -57.2% | -$171.8M -108.5% | -$82.4M -4.7% | -$78.7M -0.8% | -$78.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -521.0% -251.5pp | -269.6% -128.6pp | -141.0% +11.8pp | -152.7% +26.6pp | -179.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $18.4M -9.5% | $20.3M +409.2% | $4.0M +399.1% | $798.0K +2318.2% | $33.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $11.8M -12.8% | $13.6M +19.7% | $11.3M +61.5% | $7.0M +5.3% | $6.7M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $4.1M +118.8% | -$21.7M -1419.9% | $1.6M -78.4% | $7.6M -89.3% | $71.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$265.9M -37.4% | -$193.5M -139.7% | -$80.7M -13.7% | -$71.0M -984.1% | -$6.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -513.2% -209.5pp | -303.7% -165.5pp | -138.1% -0.2pp | -138.0% -122.9pp | -15.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$265.9M -37.4% | -$193.5M -139.7% | -$80.7M -13.7% | -$71.0M -984.1% | -$6.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -513.2% -209.5pp | -303.7% -165.5pp | -138.1% -0.2pp | -138.0% -122.9pp | -15.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -16.4% | -$1 -11.9% | -$1 -4.8% | -$1 +1.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -16.4% | -$1 -19.6% | -$1 -5.2% | -$1 +1.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $187.2M +18.3% | $158.3M +98.3% | $79.8M +3.8% | $76.9M +0.6% | $76.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $187.2M +18.3% | $158.3M +84.9% | $85.6M +3.6% | $82.6M +0.6% | $82.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
Galapagos N.V.
GLPG
$1.84B
Mesoblast Limited
NASDAQ:MESO
$1.79B
uniQure N.V.
NASDAQ:QURE
$1.74B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does OCUL generate?
Ocular Therapeutix, Inc. (OCUL) reported $51.82M of revenue in fiscal 2025.
Is OCUL profitable?
Ocular Therapeutix, Inc. (OCUL) reported -$265,939,000.00 of net income, with a net margin of -513.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.